Literature DB >> 22089315

R7BP modulates opiate analgesia and tolerance but not withdrawal.

Dimitra Terzi1, Yan Cao, Ioanna Agrimaki, Kirill A Martemyanov, Venetia Zachariou.   

Abstract

The adaptor protein R7 family binding protein (R7BP) modulates G protein coupled receptor (GPCR) signaling and desensitization by controlling the function of regulator of G protein signaling (RGS) proteins. R7BP is expressed throughout the brain and appears to modulate the membrane localization and stability of three proteins that belong to R7 RGS family: RGS6, RGS7, and RGS9-2. RGS9-2 is a potent negative modulator of opiate and psychostimulant addiction and promotes the development of analgesic tolerance to morphine, whereas the role of RGS6 and RGS7 in addiction remains unknown. Recent studies revealed that functional deletion of R7BP reduces R7 protein activity by preventing their anchoring to the cell membrane and enhances GPCR responsiveness in the basal ganglia. Here, we take advantage of R7BP knockout mice in order to examine the way interventions in R7 proteins function throughout the brain affect opiate actions. Our results suggest that R7BP is a negative modulator of the analgesic and locomotor activating actions of morphine. We also report that R7BP contributes to the development of morphine tolerance. Finally, our data suggest that although prevention of R7BP actions enhances the analgesic responses to morphine, it does not affect the severity of somatic withdrawal signs. Our data suggest that interventions in R7BP actions enhance the analgesic effect of morphine and prevent tolerance, without affecting withdrawal, pointing to R7BP complexes as potential new targets for analgesic drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089315      PMCID: PMC3280654          DOI: 10.1038/npp.2011.284

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  36 in total

1.  Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery.

Authors:  L M Bohn; L A Dykstra; R J Lefkowitz; M G Caron; L S Barak
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

2.  D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.

Authors:  Abraham Kovoor; Petra Seyffarth; Jana Ebert; Sami Barghshoon; Ching-Kang Chen; Sigrid Schwarz; Jeffrey D Axelrod; Benjamin N R Cheyette; Melvin I Simon; Henry A Lester; Johannes Schwarz
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

3.  DEP-domain-mediated regulation of GPCR signaling responses.

Authors:  Daniel R Ballon; Paul L Flanary; Douglas P Gladue; James B Konopka; Henrik G Dohlman; Jeremy Thorner
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

4.  RGS9-2 is a negative modulator of mu-opioid receptor function.

Authors:  Kassi Psifogeorgou; Paraskevi Papakosta; Scott J Russo; Rachael L Neve; Dimitris Kardassis; Stephen J Gold; Venetia Zachariou
Journal:  J Neurochem       Date:  2007-08-23       Impact factor: 5.372

Review 5.  Mammalian RGS proteins: barbarians at the gate.

Authors:  D M Berman; A G Gilman
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

Review 6.  RGS proteins and signaling by heterotrimeric G proteins.

Authors:  H G Dohlman; J Thorner
Journal:  J Biol Chem       Date:  1997-02-14       Impact factor: 5.157

7.  R7BP, a novel neuronal protein interacting with RGS proteins of the R7 family.

Authors:  Kirill A Martemyanov; Peter J Yoo; Nikolai P Skiba; Vadim Y Arshavsky
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

8.  RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons.

Authors:  Theresa M Cabrera-Vera; Salvador Hernandez; Laurie R Earls; Martina Medkova; Anna K Sundgren-Andersson; D James Surmeier; Heidi E Hamm
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-08       Impact factor: 11.205

9.  Expression and localization of RGS9-2/G 5/R7BP complex in vivo is set by dynamic control of its constitutive degradation by cellular cysteine proteases.

Authors:  Garret R Anderson; Rafael Lujan; Arthur Semenov; Marco Pravetoni; Ekaterina N Posokhova; Joseph H Song; Vladimir Uversky; Ching-Kang Chen; Kevin Wickman; Kirill A Martemyanov
Journal:  J Neurosci       Date:  2007-12-19       Impact factor: 6.167

10.  Palmitoylation regulates plasma membrane-nuclear shuttling of R7BP, a novel membrane anchor for the RGS7 family.

Authors:  Ryan M Drenan; Craig A Doupnik; Maureen P Boyle; Louis J Muglia; James E Huettner; Maurine E Linder; Kendall J Blumer
Journal:  J Cell Biol       Date:  2005-05-16       Impact factor: 10.539

View more
  13 in total

1.  RGS9-2 modulates sensory and mood related symptoms of neuropathic pain.

Authors:  Dimitra Terzi; Sevasti Gaspari; Lefteris Manouras; Giannina Descalzi; Vassiliki Mitsi; Venetia Zachariou
Journal:  Neurobiol Learn Mem       Date:  2014-08-19       Impact factor: 2.877

2.  A High-Throughput Time-Resolved Fluorescence Energy Transfer Assay to Screen for Modulators of RGS7/Gβ5/R7BP Complex.

Authors:  Brian S Muntean; Dipak N Patil; Franck Madoux; James Fossetta; Louis Scampavia; Timothy P Spicer; Kirill A Martemyanov
Journal:  Assay Drug Dev Technol       Date:  2018-04       Impact factor: 1.738

3.  Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine.

Authors:  Sevasti Gaspari; Maria M Papachatzaki; Ja Wook Koo; Fiona B Carr; Maria-Efstratia Tsimpanouli; Eugenia Stergiou; Rosemary C Bagot; Deveroux Ferguson; Ezekiell Mouzon; Sumana Chakravarty; Karl Deisseroth; Mary Kay Lobo; Venetia Zachariou
Journal:  Neuropsychopharmacology       Date:  2014-02-24       Impact factor: 7.853

4.  Orphan Receptor GPR158 Is an Allosteric Modulator of RGS7 Catalytic Activity with an Essential Role in Dictating Its Expression and Localization in the Brain.

Authors:  Cesare Orlandi; Keqiang Xie; Ikuo Masuho; Ana Fajardo-Serrano; Rafael Lujan; Kirill A Martemyanov
Journal:  J Biol Chem       Date:  2015-03-19       Impact factor: 5.157

5.  RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.

Authors:  Sevasti Gaspari; Valeria Cogliani; Lefteris Manouras; Ethan M Anderson; Vasiliki Mitsi; Kleopatra Avrampou; Fiona B Carr; Venetia Zachariou
Journal:  Neuropsychopharmacology       Date:  2017-01-11       Impact factor: 7.853

Review 6.  Regulators of G Protein Signaling in Analgesia and Addiction.

Authors:  Farhana Sakloth; Claire Polizu; Feodora Bertherat; Venetia Zachariou
Journal:  Mol Pharmacol       Date:  2020-05-30       Impact factor: 4.436

7.  Genetic behavioral screen identifies an orphan anti-opioid system.

Authors:  Dandan Wang; Hannah M Stoveken; Stefano Zucca; Maria Dao; Cesare Orlandi; Chenghui Song; Ikuo Masuho; Caitlin Johnston; Karla J Opperman; Andrew C Giles; Matthew S Gill; Erik A Lundquist; Brock Grill; Kirill A Martemyanov
Journal:  Science       Date:  2019-08-15       Impact factor: 47.728

Review 8.  RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives.

Authors:  Maciej Salaga; Martin Storr; Kirill A Martemyanov; Jakub Fichna
Journal:  Bioessays       Date:  2016-01-28       Impact factor: 4.345

9.  Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models.

Authors:  Maria Stratinaki; Artemis Varidaki; Vasiliki Mitsi; Subroto Ghose; Jane Magida; Caroline Dias; Scott J Russo; Vincent Vialou; Barbara J Caldarone; Carol A Tamminga; Eric J Nestler; Venetia Zachariou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

10.  A central role for R7bp in the regulation of itch sensation.

Authors:  Mritunjay Pandey; Jian-Hua Zhang; Santosh K Mishra; Poorni R Adikaram; Benjamin Harris; John F Kahler; Anna Loshakov; Roxanne Sholevar; Allison Genis; Claire Kittock; Juraj Kabat; Sundar Ganesan; Richard R Neubig; Mark A Hoon; William F Simonds
Journal:  Pain       Date:  2017-05       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.